Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Revenue (2020 - 2022)

Candel Therapeutics' Revenue history spans 3 years, with the latest figure at $31000.0 for Q4 2022.

  • On a quarterly basis, Revenue rose 416.67% to $31000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $124000.0, a 25.25% increase, with the full-year FY2022 number at $125000.0, up 25.0% from a year prior.
  • Revenue hit $31000.0 in Q4 2022 for Candel Therapeutics, roughly flat from $31000.0 in the prior quarter.
  • Over the last five years, Revenue for CADL hit a ceiling of $31000.0 in Q2 2020 and a floor of $6000.0 in Q4 2021.
  • Historically, Revenue has averaged $28727.3 across 3 years, with a median of $31000.0 in 2020.
  • Biggest five-year swings in Revenue: plummeted 80.65% in 2021 and later skyrocketed 416.67% in 2022.
  • Tracing CADL's Revenue over 3 years: stood at $31000.0 in 2020, then plummeted by 80.65% to $6000.0 in 2021, then skyrocketed by 416.67% to $31000.0 in 2022.
  • Business Quant data shows Revenue for CADL at $31000.0 in Q4 2022, $31000.0 in Q3 2022, and $31000.0 in Q2 2022.